Analysis of vasodilator responses to peroxynitrite in the hindlimb vascular bed of the cat

J Cardiovasc Pharmacol. 2007 Oct;50(4):358-66. doi: 10.1097/FJC.0b013e31811242cd.

Abstract

The free radical peroxynitrite (ONOO-) is formed in biological systems from the reaction of nitric oxide (NO) with superoxide (O2-) and can react with protein and nonprotein thiol groups to produce tissue injury. However, these pathologic actions of (ONOO-) may have been overemphasized, in that (ONOO-) has vasorelaxant properties through activation of soluble guanylate cyclase; inhibits leukocyte-endothelial cell interactions; and reduces ischemia-reperfusion injury in the heart, lung, and liver. It has been reported that tolerance develops to the vasodilator actions of (ONOO-) and that (ONOO-) impairs vascular function. However, little, if anything, is known about responses to (ONOO-) in the hindlimb circulation of the cat. To better understand the effects of (ONOO-) on responses to vasoactive agonists and the mechanism by which (ONOO-) induces vasodilation, the effects of short-term exposure to (ONOO-) were investigated under constant-flow conditions in the hindlimb vascular bed of the cat. In these studies, direct intraarterial injections of (ONOO-) produced dose-dependent decreases in hindquarters perfusion pressure. The vasodilator responses to (ONOO-) were rapid in onset, were short in duration, and could be repeated without exhibiting tachyphylaxis. Vasodilator responses to (ONOO-) were not changed in the presence of inhibitors of nitric-oxide synthase, cyclooxygenase, or K+-ATP (adenosine triphosphate-sensitive potassium) channels. Furthermore, responses to (ONOO-) were enhanced in duration by the type 5-cGMP (cyclic guanosine monophosphate) phosphodiesterase inhibitor zaprinast, whereas rolipram, a type 4-cGMP phosphodiesterase inhibitor, was without effect. Repeated administration of (ONOO-) had no significant effect on responses to vasoconstrictor or to vasodilator agents including acetylcholine. These results show that (ONOO-) has significant vasodilator activity in the hindlimb vascular bed of the cat and suggest that the response is mediated by a cGMP- dependent mechanism. The results of experiments with repeated injections of (ONOO-) indicate that (ONOO-) does not impair vasoconstrictor and endothelium-dependent or endothelium-independent vasodilator responses. Furthermore, tolerance did not develop with repeated short-term exposure to (ONOO-). Moreover, the results of experiments with inhibitors suggest that responses to (ONOO-) are not dependent on K-ATP (adenosine triphosphate-sensitive potassium) channel activation, increased NOS activity, or the formation of products in the cyclooxygenase pathway. The results of these studies are consistent with the hypothesis that (ONOO-) is rapidly converted in the hindlimb circulation to a substance that has the properties of an NO donor. These studies suggest that under physiologic conditions, the cytotoxic effects of (ONOO-) on a short-term basis may have been overemphasized.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors
  • Adamantane / analogs & derivatives
  • Adamantane / pharmacology
  • Animals
  • Cats
  • Female
  • Hindlimb / blood supply*
  • Hindlimb / drug effects
  • Male
  • Meclofenamic Acid / pharmacology
  • Morpholines / pharmacology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitrates / pharmacology
  • Nitric Oxide Donors / pharmacology*
  • Perfusion
  • Peroxynitrous Acid / pharmacology*
  • Phosphodiesterase Inhibitors / pharmacology
  • Potassium Channel Blockers / pharmacology
  • Purinones / pharmacology
  • Regional Blood Flow / drug effects*
  • Rolipram / pharmacology
  • Sodium Nitrite / pharmacology
  • Splanchnic Circulation / drug effects
  • Vascular Resistance / drug effects*
  • Vasoconstrictor Agents / pharmacology
  • Vasodilator Agents / pharmacology*

Substances

  • Morpholines
  • Nitrates
  • Nitric Oxide Donors
  • Phosphodiesterase Inhibitors
  • Potassium Channel Blockers
  • Purinones
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Peroxynitrous Acid
  • Meclofenamic Acid
  • U 37883A
  • sodium nitrate
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • zaprinast
  • Rolipram
  • Sodium Nitrite
  • Adamantane
  • NG-Nitroarginine Methyl Ester